Core Insights - Thermo Fisher Scientific Inc. is a leading life sciences and technology company with a market cap of approximately $193.7 billion, indicating its significant size and influence in the healthcare and diagnostics sectors [1][2] Company Overview - The company develops and supplies scientific instruments, laboratory equipment, specialty diagnostics, reagents, and biopharmaceutical services for research, healthcare, and industrial markets globally [1] - Thermo Fisher has established a dominant presence in research, diagnostics, laboratory equipment, and biopharma services, supported by substantial investments in R&D and strong integrated systems [2] Stock Performance - The stock is currently down 19.9% from its 52-week high of $643.99, reached on January 22, and has decreased 12% over the past three months, underperforming compared to the iShares US Medical Devices ETF, which declined 7.5% in the same period [3] - Year-to-date, the stock is down 11% and has fallen 3.7% over the past 52 weeks, while the IHI ETF has seen a decline of 4.1% in 2026 and 6.8% over the past year [4] Financial Performance - In Q4 2025, the company reported revenue of approximately $12.2 billion, reflecting a 7% year-over-year growth, and adjusted EPS of $6.57, an 8% increase, surpassing Wall Street estimates [6] - Full-year revenue for 2025 grew by 4% to around $44.6 billion, indicating solid earnings despite cautious guidance from the company [6]

Core Insights - Financial giants are showing a bearish sentiment towards Thermo Fisher Scientific, with 55% of traders exhibiting bearish tendencies and only 22% being bullish [1] - Significant investors are targeting a price range of $390.0 to $560.0 for Thermo Fisher Scientific over the past three months [2] Options Trading Activity - The analysis of options trading revealed 9 unusual trades, including 2 puts valued at $176,400 and 7 calls valued at $558,411 [1] - The largest options trades include bearish calls and puts, with notable trades at strike prices of $390.00 and $560.00 [7] Volume and Open Interest - Monitoring volume and open interest provides insights into the liquidity and interest in Thermo Fisher Scientific's options, particularly within the $390.0 to $560.0 strike price range over the last 30 days [3][4] Company Overview - Thermo Fisher Scientific operates in four segments: analytical technologies (17% of sales), specialty diagnostic products (11%), life science solutions (23%), and lab products and services [8] Analyst Ratings and Price Targets - Recent expert ratings suggest an average target price of $687.0, with various analysts adjusting their ratings and price targets, including Goldman Sachs lowering to $685 and Citigroup upgrading to $660 [9][10] Current Market Position - The stock is currently trading at $577.22, reflecting a 0.59% increase, with a volume of 699,377 [12]

Core Insights - Thermo Fisher Scientific Inc. (TMO) is a leading biotechnology and life sciences company with a market cap of $220 billion, providing a wide range of products and services for research, diagnostics, and laboratory operations [1][2] Financial Performance - TMO shares have retreated 2.2% from their 52-week high of $610.97, but have surged 21.8% over the past three months, outperforming the Health Care Select Sector SPDR Fund (XLV), which declined by 16.6% during the same period [3] - Year-to-date, TMO is up 14.9%, lagging behind XLV's 15.4% rise, while over the past 52 weeks, TMO shares have increased by 16.3%, surpassing XLV's 9.2% increase [4] Recent Developments - On November 24, Thermo Fisher priced a €2.1 billion ($2.4 billion) euro-denominated bond offering, which includes €1.0 billion floating-rate notes due 2027 and €1.1 billion ($1.3 billion) fixed-rate notes due 2035, aimed at funding general corporate purposes [5] - Following the bond offering announcement, Thermo Fisher's shares rose by 2% in the next trading session [5] Competitive Landscape - IDEXX Laboratories, Inc. (IDXX) has outperformed Thermo Fisher, with shares up 85.4% year-to-date and 78.9% over the past 52 weeks [6]